Southborough clinical research firm names new CEO

Veristat promotes Kim McLean Boericke to lead the company as CEO

Published on Feb. 12, 2026

Got story updates? Submit your updates here. ›

Clinical research organization Veristat has a new leader as the Southborough-based firm promoted Kim McLean Boericke to the role of CEO. Boericke most recently served as Veristat's COO and will now work to grow the company's therapeutic specializations in oncology, neurology, and rare diseases.

Why it matters

Veristat is a prominent clinical research organization that supports biotech companies in developing novel therapies. Boericke's promotion to CEO signals the company's focus on expanding its capabilities and advancing drug development programs for its clients.

The details

Boericke succeeds Patrick Flanagan, who served as Veristat's CEO for 13 years. During his tenure, Flanagan helped advance over 180 regulatory application submissions, leading to 120 approved therapies. Prior to joining Veristat in 2024, Boericke held leadership roles at other biotech research firms for more than 20 years, including serving as COO of THREAD, president of commercialization and outcomes at ICON plc, and vice president and managing director of IQVIA.

  • Boericke was promoted to CEO of Veristat in January 2026.
  • Flanagan served as Veristat's CEO for 13 years before stepping down.
  • Boericke joined Veristat in 2024 as the company's COO.

The players

Kim McLean Boericke

The new CEO of Veristat, a Southborough-based clinical research organization. Boericke previously served as Veristat's COO and has over 20 years of experience in leadership roles at other biotech research firms.

Patrick Flanagan

The former CEO of Veristat, who served in that role for 13 years. Flanagan will remain with the company as a member of its board of directors.

Veristat

A clinical research organization based in Southborough, Massachusetts that is contracted by biotech companies to support their clinical testing and drug development efforts, particularly in the areas of oncology, neurology, and rare diseases.

Got photos? Submit your photos here. ›

What they’re saying

“Veristat is unique in that it was built on a strong foundation of scientific integrity, a client focus, and high-quality clinical trial support. Kim's expertise, combined with her strategic and efficient approach to implementing solutions, will advance Veristat as the company continues to innovate and grow in supporting our clients' most complex clinical trials and the patients they serve.”

— Patrick Flanagan, Former CEO of Veristat (Veristat press release)

“Veristat is at the forefront of clinical research, and I'm excited to continue building on our company's vision to help bring the most advanced therapies to patients. My immediate focus will be on expanding Veristat's early-stage strategic consulting capabilities, enabling closer collaboration with clients to finalize and deliver drug development programs, optimize clinical trial design, and streamline regulatory pathways to approval.”

— Kim McLean Boericke, New CEO of Veristat (Veristat press release)

The takeaway

Veristat's promotion of Kim McLean Boericke to CEO signals the company's commitment to expanding its capabilities and advancing drug development programs for its biotech clients, building on the strong foundation established by former CEO Patrick Flanagan.